SCHEMBL19084686

SCHEMBL19084686

CC(=O)Nc1ccc(-c2cc(=O)n3nc(C(F)(F)F)c(-c4ccc(Cl)cc4)c3[nH]2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSD A5PKW4 8/20 0.54
ARF6 P62330 6/20 0.50
PLAT P00750 1/20 0.46
POLB P06746 2/20 0.43
KDM4E B2RXH2 2/20 0.43
MEN1 O00255 2/20 0.43
ALDH1A1 P00352 2/20 0.43
HPGD P15428 2/20 0.43
KMT2A Q03164 2/20 0.43
MAPT P10636 1/20 0.43
ATM Q13315 1/20 0.43
LMNA P02545 1/20 0.41
TP53 P04637 1/20 0.40
HSD17B10 Q99714 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
ADORA2A P29274 1/20 0.39
ADORA1 P30542 1/20 0.39
NPC1 O15118 1/20 0.39
NR1I2 O75469 1/20 0.39
AHR P35869 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19084511 0.92 PSD (0.57) PSDARF6PLAT
SCHEMBL19084675 0.91 PSD (0.55) PSDARF6PLATPOLBKDM4E
SCHEMBL19084538 0.88 ARF6 (0.58) PSDARF6PLATKDM4EMEN1
SCHEMBL19084610 0.87 PSD (0.57) PSDARF6PLATPOLBKMT2A
SCHEMBL19084502 0.87 PSD (0.57) PSDARF6PLATPOLBKDM4E
SCHEMBL1279352 0.84 ARF6 (0.59) PSDARF6PLATKDM4EMEN1
SCHEMBL1278782 0.84 ARF6 (0.58) PSDARF6PLATPOLBKDM4E
SCHEMBL19084586 0.83 ARF6 (0.53) PSDARF6PLATKDM4EMEN1
SCHEMBL19084547 0.83 ARF6 (0.53) PSDARF6PLATKDM4EMEN1
SCHEMBL19084543 0.83 PSD (0.58) PSDARF6PLATKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10849901-B2 Arf6 inhibitors and methods of synthesis and use thereof NAVIGEN, INC. (US) 2020-12-01 US disclosed
US-20170189405-A1 ARF6 INHIBITORS AND METHODS OF SYNTHESIS AND USE THEREOF NAVIGEN, INC. (US) 2017-07-06 US disclosed
US-20170189405-A1 ARF6 INHIBITORS AND METHODS OF SYNTHESIS AND USE THEREOF NAVIGEN, INC. (US) 2017-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170189405-A1 ARF6 INHIBITORS AND METHODS OF SYNTHESIS AND USE THEREOF ARF6, ARF1, ARFIP2 PSD 211/4885ARF6 1/4885PLAT 3989/4885
US-10849901-B2 Arf6 inhibitors and methods of synthesis and use thereof ARF6, ARF1, ARFIP2 PSD 211/4885ARF6 1/4885PLAT 3989/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.